Eli Lily LLYAfter the company’s stock price plummeted due to the recent data of another research in patients without diabetes, the experimental GLP-1 drug helped to lose weight by 10.5 % of the patients with an adult 2-type diabetes patients in the late stage test.
In addition, the drug, which is taken once a day, helped 75% of patients who took the highest dose of Orpopoglifon to lower the A1C, a blood glucose level, to less than 6.5% over time, which is lower than that of the US Diabetes Association’s target for most adults, less than 7%.
Orpopoglypron is a low molecular pill, which is easier to manufacture and package than the widely used obese injections, such as the engraved peptide imitation of the appetite control hormone GLP-1, Lily, and Wegobi, a competitive therapy of Novo Nordisk.
Kenneth Customer, president of the pharmaceutical’s heart metabolic health business, headquartered in Indianapolis, says the pills are a promising alternative to the injection that can be manufactured in “enormous scale.”
In a 72 -week study of more than 1,600 properties or obese adults with type 2 diabetes, patients with 36 millimeter doses of Orpopoglifon have reached 10.5%(10.43kg), and patients with placebo have reduced the main goal of clinical trials.
Patients who took 6 mg, the lowest capacity of the Lily drug, lost 5.5%of their weight.
Custom said that patients with type 2 diabetes, which are defective and obese, are generally more resistant to weight loss than patients without diabetes.
Lily said the clinical trials have a full clinical package needed to apply for the approval of Orpopoglifron in various regulators.
When asked whether Lily would apply for a priority screening voucher that could shorten the FDA’s decision on the new drug application, he said, “All options are on the table.”
According to Orpopoglifron’s initial research data for non -diabetes or obese adults, an average of 12.4%of weight loss was shown. The analysts wanted to match Wegovi’s 14.9%of the 68 weeks from 2021, and some expect this drug to exceed this.
In the latest clinical trials for high -capacity patients, the nausea ratio was 36.4%and the vomiting experience rate was 23.1%, which was higher than 8.4%and 3.8%of the placebo group, respectively. This is similar to the ratio of 33.7%nausea and 24%vomiting in previous studies, causing the stock price drop.
In the latest results, about 10% of patients with high doses were dropped from clinical trials due to side effects. As with the previous clinical trials, there was no safety issue that had been found.
Zebound and Webobi dominate the weight loss market, which some analysts expect to form a $ 150 billion in weight loss market by the early 2030s.
The US Food and Drug Administration is considering high -capacity oral Wegobi for the possibility of approval this year. Novo says it showed a 15%weight loss effect in the late clinical trial.
Lilly said in a recent test that Orpopoglifon showed that he lowered cholesterol, triglycerides and blood pressure and improved heart risk markers.
Wegovi was approved to reduce the risk of major heart problems, and Lily presented data this month showing the characteristics of the heart protection of diabetes treatments with the same main components as Jebound.
Approval of heart disease will greatly increase the possibility of insurance application of weight loss drugs.